Pharmaceutical company Glenmark Generics has confirmed that it has filed Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (FDA) to market generic versions of epilepsy drug Vimpat.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Glenmark, UCB, Vimpat, ANDA, patent infringement